Modified Chaihu Guizhi Decoction alleviates anxiety- and depression-like behaviors in mice with chronic unpredictable mild stress by inhibiting the JAK2/STAT3 signaling pathway.
10.12122/j.issn.1673-4254.2025.10.11
- Author:
Xiaotao LIANG
1
;
Xiaoshan LIANG
2
;
Yifan XIONG
1
;
Shiru XIE
1
;
Xiaoyu ZHU
1
;
Wei XIE
1
Author Information
1. School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China.
2. Department of Traditional Chinese Medicine, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China.
- Publication Type:Journal Article
- Keywords:
JAK2/STAT3;
Modified Chaihu Guizhi Decoction;
anxiety;
chronic unpredictable mild stress model;
depression;
network pharmacology
- MeSH:
Animals;
Janus Kinase 2/metabolism*;
STAT3 Transcription Factor/metabolism*;
Signal Transduction/drug effects*;
Depression/metabolism*;
Drugs, Chinese Herbal/pharmacology*;
Mice;
Male;
Mice, Inbred C57BL;
Anxiety/drug therapy*;
Stress, Psychological;
Disease Models, Animal
- From:
Journal of Southern Medical University
2025;45(10):2146-2159
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the mechanisms of Modified Chaihu Guizhi Decoction (MCGD) for ameliorating anxiety- and depression-like behaviors in a mouse model of chronic unpredictable mild stress (CUMS).
METHODS:The main chemical constituents of MCGD were identified through literature review, and network pharmacology analysis was performed to predict the potential pharmacological mechanisms of MCGD. For in vivo validation, male C57BL/6J mice were randomized into control group, CUMS model group, fluoxetine (FLX) treatment group, and low- and high-dose MCGD treatment groups (n=15), and in all but the control group, CUMS models were established by daily exposure to two randomized stressors for 28 consecutive days. Starting from 3 days prior to modeling, MCGD and fluoxetine treatments were administered daily via gavage and intraperitoneal injection, respectively. Depression- and anxiety-like behaviors of the mice were assessed using sucrose preference test, forced swim test, open field test and elevated plus maze test. The changes in mRNA expressions of the clock genes and inflammatory markers and expressions of the JAK2/STAT3 signaling proteins were detected using RT-qPCR and Western blotting, and immunofluorescence staining was used to detect microglia activation in the mice.
RESULTS:The key active compounds in MCGD identified by network pharmacology analysis included quercetin, acacetin, formononetin, nobiletin, and baicalein. GO analysis identified 607 enriched pathways, and KEGG pathway enrichment revealed significant involvement of the JAK2/STAT3 and NF-κB signaling pathways. In the mouse models of CUMS, treatment with both fluoxetine and MCGD significantly alleviated anxiety- and depression-like behaviors. MCGD treatment significantly reduced Iba1 expression, improved the inflammatory markers, reversed the decrease in clock gene circadian rhythm amplitude, and obviously downregulated the expressions of JAK2, p-STAT3, p-NF-κB, IL-1β, and IL-6 proteins.
CONCLUSIONS:MCGD effectively alleviates anxiety- and depression-like behaviors in CUMS mice by modulating the inflammatory pathways and inhibiting the JAK2/STAT3 signaling pathway.
